Pfizer has reached an agreement to acquire the sanofi-aventis worldwide rights to inhaled human insulin, which Pfizer intends to market under the trade name Exubera. The two companies were previously in a worldwide alliance to co-develop, co-promote and co-manufacture Exubera.
According to the World Health Organisation, approximately 194 million people worldwide have diabetes, and it is estimated that the number of people with the disease will more than double by 2030. The direct healthcare costs may be as much as $286 billion worldwide.
For $1.3 billion, Pfizer will acquire the sanofi-aventis worldwide Exubera rights as well as the insulin production facilities located in
Exubera is a fast-acting dry powder formulation of human insulin. It is inhaled into the lungs via the mouth pre-meal through a hand-held inhalation device which does not require batteries or electricity.
Exubera is under regulatory review in the
and
for the treatment of adults with both type 1 and type 2 diabetes. Pfizer plans to make Exubera available to patients as soon as possible following regulatory approvals.
Glasgow trial explores AR cues for autonomous road safety
They've ploughed into a few vulnerable road users in the past. Making that less likely will make it spectacularly easy to stop the traffic for...